Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up - Should You Buy?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $19.57, but opened at $20.23. Celldex Therapeutics shares last traded at $20.28, with a volume of 48,289 shares.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday, February 28th. The Goldman Sachs Group reduced their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They set a "buy" rating and a $64.00 price target on the stock. Finally, Morgan Stanley began coverage on Celldex Therapeutics in a research note on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $55.30.

Celldex Therapeutics Trading Down 0.2 %

The stock has a 50 day simple moving average of $19.09 and a 200-day simple moving average of $23.21. The firm has a market cap of $1.37 billion, a PE ratio of -8.04 and a beta of 1.59.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. The company had revenue of $1.18 million for the quarter, compared to analysts' expectations of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, equities research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Institutional Trading of Celldex Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Values First Advisors Inc. grew its position in shares of Celldex Therapeutics by 3.2% during the first quarter. Values First Advisors Inc. now owns 29,933 shares of the biopharmaceutical company's stock valued at $550,000 after purchasing an additional 924 shares in the last quarter. SG Americas Securities LLC grew its holdings in Celldex Therapeutics by 38.0% during the 1st quarter. SG Americas Securities LLC now owns 34,884 shares of the biopharmaceutical company's stock valued at $633,000 after buying an additional 9,601 shares in the last quarter. Apella Capital LLC bought a new stake in Celldex Therapeutics in the 1st quarter worth approximately $309,000. Mirador Capital Partners LP raised its holdings in shares of Celldex Therapeutics by 7.0% during the 1st quarter. Mirador Capital Partners LP now owns 127,874 shares of the biopharmaceutical company's stock worth $2,321,000 after acquiring an additional 8,382 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Celldex Therapeutics by 6.9% during the 1st quarter. Rhumbline Advisers now owns 98,266 shares of the biopharmaceutical company's stock valued at $1,784,000 after acquiring an additional 6,327 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.